CHGCY vs. GSK
Compare and contrast key facts about Chugai Pharmaceutical Co Ltd ADR (CHGCY) and GlaxoSmithKline plc (GSK).
Performance
CHGCY vs. GSK - Performance Comparison
Loading graphics...
CHGCY vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CHGCY Chugai Pharmaceutical Co Ltd ADR | 4.76% | 21.53% | 17.55% | 48.78% | -21.63% | -38.50% | 72.01% | 59.87% | 13.53% | 72.59% |
GSK GlaxoSmithKline plc | 13.45% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Fundamentals
CHGCY:
$90.58B
GSK:
$112.75B
CHGCY:
$138.25
GSK:
$2.78
CHGCY:
0.20
GSK:
19.82
CHGCY:
0.02
GSK:
1.33
CHGCY:
0.07
GSK:
3.54
CHGCY:
0.04
GSK:
6.90
CHGCY:
$1.27T
GSK:
$31.95B
CHGCY:
$937.60B
GSK:
$23.18B
CHGCY:
$661.98B
GSK:
$11.62B
Returns By Period
In the year-to-date period, CHGCY achieves a 4.76% return, which is significantly lower than GSK's 13.45% return. Over the past 10 years, CHGCY has outperformed GSK with an annualized return of 19.20%, while GSK has yielded a comparatively lower 5.74% annualized return.
CHGCY
- 1D
- 3.77%
- 1M
- -18.12%
- YTD
- 4.76%
- 6M
- 24.47%
- 1Y
- 23.00%
- 3Y*
- 31.95%
- 5Y*
- 6.93%
- 10Y*
- 19.20%
GSK
- 1D
- 1.77%
- 1M
- -6.66%
- YTD
- 13.45%
- 6M
- 30.03%
- 1Y
- 48.15%
- 3Y*
- 20.43%
- 5Y*
- 8.75%
- 10Y*
- 5.74%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CHGCY vs. GSK — Risk / Return Rank
CHGCY
GSK
CHGCY vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Chugai Pharmaceutical Co Ltd ADR (CHGCY) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CHGCY | GSK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.51 | 1.70 | -1.19 |
Sortino ratioReturn per unit of downside risk | 1.01 | 2.30 | -1.29 |
Omega ratioGain probability vs. loss probability | 1.14 | 1.29 | -0.15 |
Calmar ratioReturn relative to maximum drawdown | 0.68 | 3.25 | -2.57 |
Martin ratioReturn relative to average drawdown | 1.35 | 7.56 | -6.22 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CHGCY | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.51 | 1.70 | -1.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.21 | 0.36 | -0.15 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.60 | 0.25 | +0.34 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.57 | 0.33 | +0.24 |
Correlation
The correlation between CHGCY and GSK is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
CHGCY vs. GSK - Dividend Comparison
CHGCY's dividend yield for the trailing twelve months is around 1.54%, less than GSK's 3.19% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHGCY Chugai Pharmaceutical Co Ltd ADR | 1.54% | 1.62% | 0.86% | 0.00% | 1.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.64% | 1.41% |
GSK GlaxoSmithKline plc | 3.19% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
Drawdowns
CHGCY vs. GSK - Drawdown Comparison
The maximum CHGCY drawdown since its inception was -59.68%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for CHGCY and GSK.
Loading graphics...
Drawdown Indicators
| CHGCY | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.68% | -55.70% | -3.98% |
Max Drawdown (1Y)Largest decline over 1 year | -32.48% | -14.80% | -17.68% |
Max Drawdown (5Y)Largest decline over 5 years | -45.45% | -50.10% | +4.65% |
Max Drawdown (10Y)Largest decline over 10 years | -59.68% | -50.10% | -9.58% |
Current DrawdownCurrent decline from peak | -18.12% | -9.07% | -9.05% |
Average DrawdownAverage peak-to-trough decline | -16.00% | -18.90% | +2.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.48% | 6.37% | +10.11% |
Volatility
CHGCY vs. GSK - Volatility Comparison
Chugai Pharmaceutical Co Ltd ADR (CHGCY) has a higher volatility of 10.75% compared to GlaxoSmithKline plc (GSK) at 7.26%. This indicates that CHGCY's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CHGCY | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.75% | 7.26% | +3.49% |
Volatility (6M)Calculated over the trailing 6-month period | 26.44% | 19.71% | +6.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.54% | 28.43% | +17.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.24% | 24.74% | +8.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.26% | 22.72% | +9.54% |
Financials
CHGCY vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Chugai Pharmaceutical Co Ltd ADR and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CHGCY vs. GSK - Profitability Comparison
CHGCY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Chugai Pharmaceutical Co Ltd ADR reported a gross profit of 298.03B and revenue of 352.55B. Therefore, the gross margin over that period was 84.5%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a gross profit of 5.49B and revenue of 7.90B. Therefore, the gross margin over that period was 69.5%.
CHGCY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Chugai Pharmaceutical Co Ltd ADR reported an operating income of 172.47B and revenue of 352.55B, resulting in an operating margin of 48.9%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported an operating income of 179.89M and revenue of 7.90B, resulting in an operating margin of 2.3%.
CHGCY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Chugai Pharmaceutical Co Ltd ADR reported a net income of 147.51B and revenue of 352.55B, resulting in a net margin of 41.8%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a net income of 627.73M and revenue of 7.90B, resulting in a net margin of 7.9%.